Publication | Closed Access

INNO-206, the (6-maleimidocaproyl hydrazone derivative of doxorubicin), shows superior antitumor efficacy compared to doxorubicin in different tumor xenograft models and in an orthotopic pancreas carcinoma model

Tumor BiologySuperior Antitumor EfficacyMedicinePharmacologyPathology6-Maleimidocaproyl Hydrazone DerivativePharmacotherapyAnti-cancer AgentTumor TargetingCancer TreatmentOncologyCancer ResearchDrug Discovery